Introduction
The TNF-family death ligands TNF-a, CD95L/FasL and TRAIL promote apoptosis in many types of tumor and virus-infected cells. Remarkably, primary or non-transformed cells are often resistant to the death receptor-induced apoptosis, yet they express functional receptors for these ligands (LeBlanc and Ashkenazi, 2003; Fesik, 2005) . The death receptor ligands can promote regression of tumors in vivo, which in part is attributable to the selective tumor cell killing by these agents. However, only TRAIL induces tumor regression without exhibiting significant systemic toxicity in vivo, and currently both TRAIL and agonistic antibodies to TRAIL receptors are in clinical trials for the treatment of cancer (Fesik, 2005) . Despite years of intense study, only little is known about mechanisms that render tumor cells sensitive to TRAIL.
TRAIL kills cancer cells by binding specific cell surface death receptors, which are TNFRSF10A (DR4) and TNFRSF10B (DR5). After binding TRAIL, these transmembrane receptors form trimeric complexes and assemble a death-inducing signaling complex (DISC) in their cytosolic parts (LeBlanc and Ashkenazi, 2003) . DISC is a primary signaling complex in which an adaptor protein FADD mediates recruitment of cysteine protease procaspase-8 to the receptors. FADD interacts with procaspase-8 through homotypic death effector domain interactions and promotes oligomerization-dependent auto-activation of this caspase. The active caspase-8 can initiate an apoptotic caspase cascade. In addition, TRAIL may also induce activation of other signaling pathways. For example, JNK, p38 MAPK and IKK/NF-kB kinase pathways are activated downstream of DISC assembly and caspase-8 activation (Varfolomeev et al, 2005) . The kinase pathways may control apoptosis but also mediate non-apoptotic, for example proliferative or inflammatory, effects of death ligands (Algeciras-Schimnich et al, 2002; LeBlanc and Ashkenazi, 2003; Wajant et al, 2003; Secchiero et al, 2005) . The DISC-activated caspase-8 connects to the downstream apoptotic death machinery in two ways. In certain cells (Type I), DISC assembly generates large amounts of active caspase-8, which is sufficient to directly cleave and activate downstream effector caspases, such as caspases-3, -6 and -7, that execute the apoptotic death program. In other cell types (Type II), death receptor-induced apoptosis requires engagement of the mitochondria-mediated pathway into the process of cell death (Scaffidi et al, 1998 (Scaffidi et al, , 1999 Fulda et al, 2002; Rudner et al, 2005) . The active caspase-8 can cleave proapoptotic Bcl-2 family protein Bid into an active form called truncated Bid (tBid). The tBid, in turn, recruits the mitochondrial pathway by activating the distal proapoptotic Bcl-2 family proteins Bax and Bak at the mitochondrial membranes, which leads to the release of apoptosis promoting factors such as holocytochrome c (cyt c), Smac/DIABLO and Omi/HtrA2 from mitochondria to the cytosol (Lowe et al, 2004) . Once released into the cytosol, cyt c activates via APAF-1/caspase-9 complex effector caspases that execute apoptosis. TRAIL-induced apoptosis is often crucially dependent on the intact mitochondrial pathway (Deng et al, 2002; LeBlanc et al, 2002) .
Activation of c-Myc renders primary and non-transformed cells sensitive to TNF-a, CD95L and TRAIL-induced apoptosis (Hueber et al, 1997; Klefstrom et al, 1997; Ricci et al, 2004; Wang et al, 2004) . The molecular mechanisms underlying this apoptotic sensitization are not well understood, but they may involve an inhibitory action of c-Myc towards TNFinduced NF-kB activation, which normally counteracts the apoptotic action of TNF (Klefstrom et al, 1997; You et al, 2002) . c-Myc may also augment TRAIL-dependent activation of caspase-8 through transcriptional inhibition of FLIP (FLICE inhibitory protein), which antagonizes generation of active caspase-8 in DISC (Ricci et al, 2004) . However, as c-Myc sensitizes cells to a wide variety of apoptotic insults including death receptors, serum-deprivation and genotoxic agents, it is conceivable that the mechanisms of c-Myc-dependent sensitization derive from a common root. The anti-poptotic Bcl-2 family proteins, Bcl-2 and Bcl-x L , accelerate c-Myc-induced tumorigenesis by inhibiting c-Myc-dependent apoptosis (Pelengaris et al, 2002) . These data implicate a close link between c-Myc and the mitochondrial apoptosis pathway. Consistent with this, activation of a conditional form of Myc (MycER TM ) induces a rapid cyt c release in growth factordeprived cells (Juin et al, 1999; Iaccarino et al, 2003) . The upstream mechanisms triggering cyt c release involve conformational change and oligomerization of Bax and Bak proteins at the mitochondrial surface. More upstream, the activation of Bax/Bak complexes is promoted by upstream proapoptotic messengers tBid and Bim and antagonized by Bcl-2 and Bcl-x L (Lowe et al, 2004 ). Bax appears to orchestrate the apoptotic c-Myc pathway, as ablation of bax genes renders cells resistant to c-Myc-dependent apoptosis and vice versa the Bax protein promotes the apoptotic activity of c-Myc (Mitchell et al, 2000; Juin et al, 2002) . c-Myc may transcriptionally regulate Bax levels or more indirectly, regulate Bax pathway by controlling Bax oligomerization (Mitchell et al, 2000; Annis et al, 2005) . In some cells c-Myc may also sensitize cells to apoptosis by downregulating Bcl-2 or Bcl-x L expression levels (Eischen et al, 2001; Maclean et al, 2003) . Taken together, there is substantial evidence that c-Myc primarily sensitizes cells to apoptosis by activating the mitochondrial apoptosis pathway.
In this study, we show that treatment of fibroblasts and mammary epithelial cells with TRAIL weakly activates caspase-8 without killing the cells. However, c-Myc promotes activation of the mitochondrial proapoptotic Bcl-2 protein Bak, and we show evidence that in such conditions even weak TRAIL-induced caspase-8-Bid signals are sufficient to activate Bak/Bax complexes. The ensuing cyt c release and activation of effector caspases then postmitochondrially augment caspase-8 activation independently of DISC. Thus, c-Myc-mediated priming of the mitochondria pathway enables weak caspase-8 signals to activate effector caspases and establish a death executing caspase feedback amplification loop.
Results

c-Myc sensitizes cells to TRAIL by activating the mitochondrial apoptosis pathway
To explore mechanisms whereby c-Myc sensitizes cells to TRAIL, we retrovirally introduced a hydroxytamoxifen (4-OHT)-inducible MycdeltaER tm construct into human immortal, non-transformed MCF10A mammary epithelial cells. Addition of 4-OHT to growth factor-deprived MCF10A-MycER tm cells induced cell cycle re-entry, whereas the controls expressing N-terminally deleted and functionally inactive Myc mutant (MycER tm ) remained quiescent (Partanen et al, manuscript in preparation). Thus, we conclude that MycER tm is functional in the studied cells. In addition to epithelial cells, we also used telomerase-immortalized human MRC5hT fibroblasts expressing MycER tm . Neither of these cell types showed apoptotic response to the activation of MycER tm in cultures maintained in normal growth medium ( Figure 1A ). However, if c-Myc was preactivated and subsequently TRAIL was added to the cells, a widespread apoptosis occurred in both cell cultures. TRAIL alone, without c-Myc, did not induce any significant apoptosis. In further control experiments, the 4-OHT-induced activation of MycdeltaER tm failed to sensitize cells to TRAIL (data not shown). Thus, c-Myc and TRAIL synergistically induced apoptosis. Apoptosis was blocked by the pan-caspase inhibitor zVAD-fmk, which indicates a caspasedependent form of apoptosis ( Figure 1A) .
To determine whether the mitochondrial apoptosis pathway was activated, we analyzed the conformational activation of Bax (6A7 antibody, Trevigen) at the mitochondria and the sub-cellular localization of cyt c. Figure 1B shows that both Bax activation and release of cyt c from mitochondria to the cytosol required active c-Myc and TRAIL. To determine whether activation of the mitochondrial apoptosis pathway was required for the apoptotic cooperation of c-Myc and TRAIL, we generated MRC5-hT-MycER tm and MCF10A-MycER tm cells overexpressing Bcl-x L ( Figure 1B and C). Experiments with these cells showed that Bcl-x L blocks or strongly inhibits the ability of c-Myc and TRAIL to induce Bax activation, cyt c release ( Figure 1B , D and E) and apoptosis (data not shown). Thus, we conclude that c-Myc and TRAIL induce apoptosis by synergistically activating Bax and cyt c release.
c-Myc augments TRAIL-induced activation of procaspase-8 by a mechanism requiring activation of the mitochondrial apoptosis pathway To gain insight into the activation pattern of caspase machinery, we analyzed whether c-Myc influences the ability of TRAIL to induce proteolytic activation of proximal caspase-8, its target Bid and downstream effector caspase-3.
In fibroblasts, TRAIL induced weak but reproducible cleavage of procaspase-8 into the active p43/p41 and p18 subunits (Figure 2A ; note lane MYC OFF, 50 ng/ml TRAIL). Although processing of caspase-8 occurred without active c-Myc, it was notable that preactivation of c-Myc markedly enhanced the TRAIL-induced processing of procaspase-8 in these cells ( Figure 2A ). As cells did not undergo apoptosis without active c-Myc, we determined whether TRAIL alone induced not only processing, but also the activity of caspase-8. Cells were treated as indicated in Figure 2A and the IETDpNa (preferred caspase-8 substrate) cleavage activity present in cell lysates was measured. In fibroblasts, TRAIL induced about 2.4-fold increase in the proteolytic activity towards IETD peptide (Figure 2A ). In comparison, TRAIL and active c-Myc induced over six-fold increase in the IETDase activity. In mammary epithelial cells, 50 ng/ml of TRAIL induced caspase-8 cleavage and 1.6-fold increase in the IETD cleavage activity (Figure 2A ). However, if c-Myc was active, over 2.5-fold increase was observed. Furthermore, 10 ng/ml concentration of TRAIL induced detectable procaspase-8 cleavage in mammary cells only if c-Myc was active ( Figure 2A ). Thus, c-Myc is not required for TRAIL-induced activation of procaspase-8, but the presence of active c-Myc strongly augments the TRAIL-induced activation of this caspase. Downstream of caspase-8, we observed that the activity of both c-Myc and TRAIL was required for the induction of detectable proteolytic processing of Bid and activation of caspase-3 ( Figure 2B ).
Next, we wished to determine whether the mechanism by which c-Myc augments TRAIL-induced caspase-8 activation operate upstream or downstream of the activation of the mitochondrial pathway. We reasoned that if c-Myc augments the processing of caspase-8 upstream of the mitochondria, for example in DISC, the blockade of the mitochondrial pathway would not inhibit this augmentation. Strikingly, Bcl-x L completely blocked the ability of c-Myc to augment TRAILinduced caspase-8 processing and activation in fibroblasts ( Figure 2C ; see Figure 4B for IETDase activity). In addition, Bcl-x L also blocked the c-Myc-dependent processing of Bid and activation of caspase-3 by TRAIL ( Figure 2C ). In the epithelial cells, Bcl-x L inhibited the c-Myc-dependent augmentation of caspase-8 processing and reduced the ability of c-Myc and TRAIL to generate active caspase-3. These results agree with the previously published data showing that c-Myc can augment the processing of procaspase-8 into its active forms in TRAIL-treated cells (Ricci et al, 2004) . However, in contrast to the previously published data suggesting that the augmented processing of caspase-8 results from genetic interaction between FLIP and c-Myc affecting the DISC, our present data imply that postmitochondrial mechanisms, which act downstream of the activation of the mitochondrial pathway, primarily result in the enhancement of caspase-8 activity.
Caspase-8-Bid axis activates Bax and cyt c release during c-Myc and TRAIL-induced apoptosis TRAIL-induced activation of caspase-8 occurred without c-Myc, whereas surprisingly, the cleavage of Bid required both TRAIL and active c-Myc (Figure 2A and B). However, it is possible that the immunoblot analyses failed to detect a weak processing of Bid by the non-augmented caspase-8 Figure 1A and the cell lysates were analyzed for procaspase-8 cleavage and for proteolytic activity towards Ac-IETD-pNa. The immunoblot analysis shows that active c-Myc enhances TRAIL-induced cleavage of procaspase-8 into the active subunits (p43/p41 and p18). The caspase-8 antibody used recognized full-length procaspase-8 in MRC5 cells, but for some reason only weakly in MCF10A cells. However, the cleavage products that were diagnostic for caspase-8 activation were reliably detected in both cell types. The boxed values represent relative caspase-8 activities extracted from the datasets in Figure 4B . (B) Bid and caspase-3 activation. The immunoblot analyses of Bid cleavage using an antibody recognizing both full length and truncated forms of Bid and caspase-3 activation with an antibody recognizing active processed form. (C) The cells overexpressing Bcl-x L were treated as in A and analyzed for procaspase-8 processing. The immunoblots demonstrate that c-Myc fails to augment TRAIL-induced processing of procaspase-8 in the cells overexpressing Bcl-x L . activity (Myc OFF, TRAIL ON). Therefore, we undertook a genetic approach to determine whether the caspase-8-Bid axis is essential for Bax activation.
For this purpose, we created lentiviral constructs expressing short-hairpin (sh) RNAs targeting either caspase-8 or Bid (Figure 3 ). The analysis of transduced cells showed that Figure 3B and C) and apoptosis (data not shown). To suppress Bid expression, we used pDSL lentivector, allowing hygromycin selection of the transduced cells. Following selection, no detectable expression of Bid could be observed ( Figure 3D ). In the absence of Bid, the combined action of TRAIL and c-Myc failed to activate Bax or induce cyt c release ( Figure 3E -G) or induce apoptosis (data not shown). In summary, these results show that the c-Mycdependent induction of apoptosis by TRAIL requires caspase-8-Bid axis to mediate the signals that activate Bax at the mitochondria and release cyt c.
c-Myc fails to augment TRAIL-induced procaspase-8 activation in Bid-deficient cells
The results in Figure 2 suggest that mechanisms operating downstream of the mitochondrial pathway lead to augmentation of procaspase-8 processing. Thus, blockade of Bid that mediates apoptotic signaling from caspase-8 to mitochondrial Bax and Bak complexes should also prevent the c-Mycdependent augmentation of caspase-8 processing and activity. Indeed, in the Bid-deficient cells, TRAIL and c-Myc induced only basal level of caspase-8 processing ( Figure 4A ) and IETD cleavage activity ( Figure 4B ). Furthermore, both Bid knockdown and overexpression of Bcl-x L produce very similar augmentation deficiency ( Figure 4A and B) . The results strongly suggest that elements downstream of the mitochondrial pathway activation result in the augmented caspase-8 activation in the cells with both c-Myc and TRAIL pathways active.
c-Myc augments caspase-8 activity independently of the DISC In DISC, FADD coordinates oligomerization of inactive procaspase-8 zymogens, and it is considered that the zymogen dimerization is the crucial event needed for formation of active caspase-8 (Boatright et al, 2003) . However, alternative mechanisms for caspase-8 activation have also been proposed-for example, the mitochondria-mediated pathway activates caspase-8 through a mechanism involving an interchain cleavage of procaspase-8 by effector caspases-3 and -6 (Sohn et al, 2005) . Our results linking the c-Myc-dependent augmentation of caspase-8 activation to the mitochondrial pathway led us to explore whether caspase-8 was processed outside of the DISC. For these experiments, we created a conditionally active form of procaspase-8, called Fv-caspase-8. The construct consists of heterologous Fv (modified FKBP) dimerization domains fused to protease domains of procaspase-8. The Fv domains bring the whole construct under dimerization control of small molecule FKBP dimerizers Yang et al, 1998) . However, as the construct is lacking death effector domains (DED) needed for interaction with FADD, it cannot be recruited to DISC. The Fv-caspase-8 construct was cotransfected with control or wild-type c-Myc expression plasmid into 293FT cells and a small molecule AP20187 (AP) dimerizer was administered to the cells to activate Fv-caspase-8. The microscopic analysis of transfected cells showed that active Fv-caspase-8 construct synergized with c-Myc overexpression in the induction of apoptosis ( Figure 5A ). In control experiments, the catalytically inactive Fv-mut-caspase-8 failed to synergize with c-Myc ( Figure 5A ). Immunoblot analysis of Fv-caspase-8 processing showed that AP treatment generates p44 and p18 active subunits, indicating formation of active caspase-8 ( Figure 5B ). Strikingly, overexpression of c-Myc with APinduced Fv-caspase-8 strongly enhanced the generation of p44 and p18 subunits and IETD cleavage activity ( Figure 5B and C), which coincidenced with prominent caspase-3 activity ( Figure 5B and D) . The caspase-3 activation in these conditions is consistent with the widespread cell death observed in the cultures ( Figure 5A ). These results indicate that c-Myc augments caspase-8 processing independently of the DISC platform.
Loss-of antiapoptotic Bcl-2/Bcl-x L activity sensitizes cells to TRAIL and augments the caspase-8 activity A plausible explanation for the above results is that c-Myc enables TRAIL to activate Bax/Bak complexes and the subsequent activation of the mitochondria pathway and downstream effector caspases catalyzes caspase-8 activation in a feedback loop fashion. To test the hypothesis, we explored whether the sensitizing action of c-Myc can be phenocopied by chemical sensitization of Bax/Bak complexes. In these experiments, we used a cell permeant small molecule ABT-737, which lowers the activation threshold of Bax/Bak by antagonizing major antiapoptotic Bcl-2 family members (Bcl-2, Bcl-x L and Bcl-w) (Oltersdorf et al, 2005; Certo et al, 2006) . We pretreated MCF10A cells with ABT-737 and subsequently, added TRAIL to the cultures. Figure 6 shows a prominent apoptosis in the cells with activated TRAIL pathway and sensitized Bax/Bak complexes ( Figure 6A ). Neither TRAIL nor ABT-737 induced any significant apoptosis alone. We also observed that ABT-737 strongly promoted the ability of TRAIL to induce caspase-8 processing ( Figure 6B ) and IETDase activity ( Figure 6C) . Furthermore, the level of augmentation obtained with ABT-737 was comparable to that observed with c-Myc ( Figure 6C ). Thus, ABT-737 can both sensitize cells to TRAIL and enhance the activation of caspase-8. Therefore, c-Myc and ABT-737 may sensitize cells to TRAIL via similar Bax and Bak involving mechanisms.
c-Myc induces and activates Bak protein, which mediates sensitization to TRAIL
Finally, we sought to find mechanisms through which c-Myc enables activation of the mitochondrial pathway by TRAIL. We first explored whether c-Myc activation affects the protein expression levels of six different Bcl-2 family proteins Bim EL , Bid, Bax, Bak, Bcl-x L and Puma ( Figure 7A ). c-Myc strongly upregulated the levels of Bak protein in both fibroblasts and epithelial cells. The upregulated levels peaked after 10 h of c-Myc activation and within 24 h the Bak expression Figure 7B ). When the effects of TRAIL and c-Myc were examined separately, we also found that c-Myc activation alone activated Bak ( Figure 7B ). The immunostaining signal indicating Bak N-terminal exposure was not as strong in the cells with active c-Myc as compared with the cells with active c-Myc and TRAIL, but the signal was clearly detected in over 20% of the cells after 24 h c-Myc activation ( Figure 7C ). Next, we silenced Bak by shRNA lentiviruses to determine whether Bak is required for c-Myc-induced sensitization to TRAIL ( Figure 8A ). Loss-of Bak almost completely inhibited TRAIL and c-Myc-induced Bax activation, cytochrome c release and caspase-3 activation ( Figure 8B-D) . Furthermore, c-Myc failed to augment TRAIL-induced caspase-8 processing in the Bak-deficient cells ( Figure 8E ). Our results suggest that the c-Myc-dependent activation of Bak is part of the machinery through which c-Myc primes mitochondrial pathway for activation ( Figure 9 ).
Discussion
There is emerging evidence that crosstalk between the mitochondrial and death receptor apoptosis pathways determines whether cells survive or die in response to TRAIL. For example, impairment of the mitochondrial pathway through spontaneous loss of Bax allows tumor cells to escape the therapeutic cytotoxicity of TRAIL (LeBlanc et al, 2002) . However, it has remained unclear why TRAIL-induced signaling pathways in some cells activate the mitochondrial pathway and kill, whereas other cell types survive from TRAIL treatment. Do ligand-bound TRAIL receptors activate completely different set of pathways in cells that survive as compared with cells that die and if not, at which point the signaling pathways bifurcate? Interestingly, in cell-free assays, re-addition of a mitochondrial fraction into cell lysates has been shown to significantly lower the concentration of active recombinant caspase-8 needed to activate downstream caspases (Kuwana et al, 1998) . Therefore, the mitochondrial pathway does not just passively route death receptor signals to the effector caspases, but instead the mitochondria-specific mechanisms may actually set a threshold for caspase-8 activity that is needed to activate effector caspases.
TRAIL-caspase-8-Bid and c-Myc-Bak signaling modules cooperate to release cytochrome c c-Myc sensitizes cells to all death receptors that use caspase-8 for signaling (Hueber et al, 1997; Klefstrom et al, 1997; AzaBlanc et al, 2003; Ricci et al, 2004) , and there is previous evidence that c-Myc activates the mitochondrial pathway for cyt c release (Juin et al, 2002; Klefstrom et al, 2002) . Therefore, we postulated that the apoptotic cooperation of c-Myc and TRAIL involves differential sensitivity of 'mitochondria primed' and 'mitochondria non-primed' cells to caspase-8. Consistent with this model, our data show that TRAIL induces a weak activation of caspase-8, but these signals fail to activate the mitochondrial pathway as indicated by lack of Bax or Bak activation or release of cyt c. However, activation of c-Myc enables TRAIL-caspase-8-Bid axis to induce Bax activation, which subsequently promotes cyt c release, leading to caspase-3 activation and finally apoptosis. How would c-Myc enable weak TRAIL-caspase-8 signaling to activate Bax? Our results show that activation of c-Myc transiently upregulates Bak protein and exposes the N terminus of Bak, which reflects activation or transition of Bak towards active state. Furthermore, c-Myc-induced Bak remained in this active state long-term (424 h) and after the Bak protein levels were already returned to the basal level. As Bak is required for c-Myc and TRAIL-induced Bax activation (Figure 8) , we believe that Bak is part of the machinery through which c-Myc 'primes' the mitochondrial pathway. tBid can promote oligomerization of both Bax and Bak (Wei et al, 2000) , and the detailed nature of complexes forming at the mitochondria during c-Myc and TRAIL induced apoptosis remains to be clarified. However, we speculate that TRAILinduced increase in the immunoreactivity of Bak N terminus, which specifically occurred in the cells with c-Myc is due to formation of high-order Bak complexes (Mikhailov et al, 2003; Ruffolo and Shore, 2003) . Therefore, the weak c-Mycinduced immunostaining may indicate formation of preactive Bak mono-or oligomers (Zhang et al, 2004) . It is notable, that previous studies have already implicated a role for c-Myc in However, oncogenic c-Myc or specific drugs can preactivate Bak and in these conditions even a weak activation of caspase-8 and Bid fully activates formation of Bak/Bax complexes, which triggers release of cyt c and subsequently recruits downstream effector caspases. Downstream effector caspases cleave vital cellular substrates and generate substantially more caspase-8 activity through interchain cleavage, which results in strong Bid activation. We propose that the onset of such caspase feedback loop represents a phase transition, where apoptosis becomes a TRAIL-independent cell autonomous process. These mechanisms may have evolved to ensure that the progression of late stage apoptosis is not dependent on the extracellular availability of death ligands. The model is illustrated in the figure as a process diagram with graphical notation system (Kitano et al, 2005 the regulation of Bax oligomerization (Soucie et al, 2001; Annis et al, 2005) . Previous reports have documented that c-Myc elevates protein expression levels of Bim and Bax (Mitchell et al, 2000; Hemann et al, 2005) or downregulates Bcl-x L (Maclean et al, 2003) , which changes were not observed in this study. It is very likely that c-Myc alters the balance of pro-and antiapoptotic Bcl-2 proteins in a different manner depending on the cell type or cellular response to c-Myc in given conditions (apoptotic vs non-apoptotic).
TRAIL-induced caspase-8 activity is augmented at the postmitochondrial stage of apoptosis Recent data have suggested that a direct transcriptional downregulation of FLIP by c-Myc results in enhanced caspase-8 processing in DISC (Ricci et al, 2004) . However, our transcriptional profiling of MCF10A-MycER tm cells failed to detect any c-Myc-dependent alterations in FLIP levels (data not shown). Furthermore, the absence of FLIP in a public database of compiled c-Myc target genes may indicate that FLIP is not a common target for transcriptional regulation by c-Myc (http://www.myccancergene.org/). The present data show that c-Myc fails to augment caspase-8 activity in the cells containing mitochondrial pathway defects related to Bid-or Bak-deficiency or Bcl-x L overexpression. Therefore, in fibroblasts and epithelial cells, mechanisms acting downstream or at the level of activation of the mitochondrial pathway augment caspase-8 cleavage. Sohn et al (2005) have shown evidence that during druginduced apoptosis, caspase-8 is activated in the absence of DISC formation by a mechanism involving interchain cleavage performed by effector caspases-3 and -6. This and previous studies by Slee et al (2000) postulate that the effector caspases, which are activated at the postmitochondrial stage of apoptosis, activate the death receptor proximal effectors caspase -8 and Bid ( Sohn et al, 2005) . The significance of such caspase feedback amplification loop for apoptosis has been recently underscored by findings that mouse embryonic fibroblasts deficient in caspase-3 and -7 show pronounced delay in the kinetics of cyt c release and Bax translocation in response to UV radiation (Lakhani et al, 2006) . In the present study, we show that c-Myc-induced augmentation of caspase-8 cleavage and activity requires an intact mitochondrial pathway but not DISC. Therefore, most likely the action of effector caspases acting at the postmitochondrial stage of apoptosis caused the augmented cleavage and activation of caspase-8 in the present model system.
The reason why caspase feedback loop is coupled to apoptotic TRAIL machinery could be related to the use of TRAIL-caspase-8 signaling not only for death induction, but also for non-apoptotic TRAIL responses (Varfolomeev et al, 2005; Trauzold et al, 2006) . We suggest that in normal cells it is important to keep the caspase-8 activity carefully in check to control non-apoptotic TRAIL responses and to avoid death. However, when TRAIL-induced activation of caspase-8-Bid axis leads to cyt c release, for example in transformed cells, consequent activation of effector caspases establishes a caspase feedback amplification loop, which now recruits caspase-8 into death execution process. Thereafter, the process of dying is not anymore controlled by the extracellular availability of TRAIL ligand, but instead, the apoptotic feedback loop drives apoptosis in an autonomous manner ensuring completion of death process. The cell-autonomous execution phase in apoptosis may ensure that once cells have entered the point-of-no-return stage, changing extracellular conditions do not interrupt the process of dying.
Mitochondria-priming model
In summary, we propose a mitochondria-priming model in Figure 9 to explain mechanisms whereby c-Myc enables TRAIL to fully activate caspase machinery in human cells. The presented model can generally explain the synergistic induction of apoptosis by active c-Myc and any death receptor recruiting caspase-8 for signaling.
Materials and methods
Generation of cDNA and shRNA expressing stable cell lines Human non-transformed MCF10A mammary epithelial cell line and MRC5 human fibroblast cells were obtained from ATCC. Immortal MRC5 cells (MRC5hT) were generated by retroviral introduction of human telomerase reverse transcriptase subunit/hTERT into these cells (the pWZL-hTERT construct was a kind gift from Drs Martin McMahon, UCSF and Robert A Weinberg, Whitehead/MIT). The 4-OHT (but not estrogen)-inducible MycER TM construct in pBabepuro retrovirusvector was a kind gift from Gerard Evan, UCSF. The pBabeMycER TM construct was retrovirally introduced in the studied cells and the cells were selected in 2.5 mg/ml puromycin. The clones surviving in selection were pooled for assays. The pBabehygro Bcl-x L (gift from Gerard Evan, UCSF) overexpressing cells were generated with similar procedures except for the selection carried out in 200 mg/ml hygromycin. For caspase-8 silencing, we used pLentiLox3.7 (pLL3.7) vector (http://web.mit. edu/ccr/labs/jacks/protocols/rnairesources.htm) with shRNA targeting sequence 5 0 -CAGGGTCATGCTCTATCAGATTT-3 0 . For Bid and Bak silencing, we used pDSL_hpUGIH (AFCS, http://www.signalinggateway.org) vector expressing shRNA targeting Bid sequence 5 0 -ACA GAATCCGCACTGTGCTcc-3 0 and Bak sequence 5 0 -CATAGCGTCGGTT GATGTCgt-3 0 .
Generation of Fv-caspase-8 constructs
The protease domains of caspase-8 and caspase-8 C-A mutant (catalytic site cysteine mutated into an alanine) were PCR amplified from pcDNA3.1-Caspase 8 and pcDNA3.1-Caspase 8 C-A vectors.
Resulting fragments were digested and subcloned into pC4M-Fv2E (Ariad Pharmaceuticals). The two Fv (FKBP variant) domains in the chimeric Fv2E-caspase-8 construct substitute for the natural DED dimerization domains of caspase-8 and allow ectopic dimerization of the construct with chemical dimerizer AP20187. The sequences of pC4M-Fv2E-caspase-8 and pC4M-Fv2E-caspase-8 C-A constructs were verified by sequencing.
Reagents
To activate MycER tm , cells were treated with 10 nM 4-hydroxytamoxifen (Sigma). The recombinant human soluble TRAIL was from R&D Systems. To activate Fv constructs, cells were treated with 100 nM AP20187 (Ariad). Cells were incubated with 50 mM of the pan-caspase inhibitor z-VAD-fmk (Enzyme Systems Products) to inhibit caspases. To inhibit Bcl-2, Bcl-x L and Bcl-w, we used a small molecule inhibitor ABT-737 at 1 mM concentration (a kind gift from Dr Steven W Elmore, Abbott Laboratories).
Immunofluorescence microscopy, image acquisition and data analysis Cells were stained with anti-cytochrome c (Pharmingen), anti-active Bax (6A7, Trevigen), anti-active Bak (Ab-1, Calbiochem), antiactive caspase-3 (Cell Signaling) and Hoechst 33258 (Sigma). Secondary antibodies used were Alexa-488 or -546 (Molecular Probes). Staining protocols, image acquisition and data analysis are explained in Supplementary data.
Western immunoblot analyses
Cell lysates were prepared using non-ionic Triton-X cell lysis buffer (10 mM Tris, pH 7.5, 130 mM NaCl, 1% Triton X-100, 10 mM NaP i and 10 mM Napp i ). The monoclonal antibodies used for immunodetection were anti-caspase-8 (Cell Signaling Technology, abbr.
